Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019148 · ClinicalTrials.gov registry record
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
A clinical trial of Epidermolysis Bullosa Dystrophica, sponsored by Stanford University.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT01019148: Recruiting study of Epidermolysis Bullosa Dystrophica, sponsored by Stanford University.
NCT01019148 is a study of Epidermolysis Bullosa Dystrophica that is actively recruiting participants, run by Stanford University. The registered enrollment target is 70 participants, above the 24-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (192% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01019148, a study of Epidermolysis Bullosa Dystrophica, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Primary Outcome
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa for future studies
Conditions Studied
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-11-10 |
| Est. Completion | 2029-12-31 |
What NCT01019148 shows while recruiting
NCT01019148 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 24-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (192% higher).
The record links to 1 condition, with Epidermolysis Bullosa Dystrophica appearing as the primary indexed condition, and to 0 interventions.
NCT01019148 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01019148 about?
NCT01019148 is a clinical study titled "Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa". Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics o...
What is the current status of trial NCT01019148?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2009-11-10. Estimated completion is 2029-12-31.
What conditions does trial NCT01019148 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa Dystrophica.
Who is sponsoring clinical trial NCT01019148?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01019148 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa Dystrophica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI